戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tom characteristic of dcSSc with and without Raynaud's phenomenon).
2 ing significant changes in the management of Raynaud's phenomenon.
3 sure, myopic refractive error (for NTG), and Raynaud's phenomenon.
4 y hypertension are also showing an effect in Raynaud's phenomenon.
5  occupational origin and a form of secondary Raynaud's phenomenon.
6 anoids are being tested for the treatment of Raynaud's phenomenon.
7  disease, including risk of hypertension and Raynaud's phenomenon.
8 itical digital ischemia) in the treatment of Raynaud's phenomenon all determined improvement of sympt
9                             All patients had Raynaud's phenomenon and 82% had gastrointestinal (GI) i
10 er time; features of inflammation as well as Raynaud's phenomenon and esophageal hypomotility diminis
11 gives an update of the current management of Raynaud's phenomenon and its ischaemic complications (di
12                 PHT patients had more severe Raynaud's phenomenon and more severe digital tip ulcers,
13 551 and +1922 demonstrated correlations with Raynaud's phenomenon and pulmonary fibrosis, respectivel
14  have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia.
15  congestive heart failure, stroke, dementia, Raynaud's phenomenon, and all-cause mortality.
16 ancy, she developed multiple autoantibodies, Raynaud's phenomenon, and fetal death occurred at 20 wee
17 linically the condition differs from primary Raynaud's phenomenon as persistent pain and paresthesia
18 discrimination between primary and secondary Raynaud's phenomenon as well as a better way to predict
19                All patients had a history of Raynaud's phenomenon, as well as elevated anticardiolipi
20                                Acrocyanosis, Raynaud's phenomenon, chilblain lesions, low-pitch hoars
21 l randomized trials of PDE5Is, patients with Raynaud's phenomenon demonstrated improved blood flow, f
22       New potential targets for treatment of Raynaud's phenomenon derive from experimental observatio
23                           CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodact
24     It is characterized by calcinosis cutis, Raynaud's phenomenon, esophageal involvement, sclerodact
25 migraine, coronary spasm, lupus, vasculitis, Raynaud's phenomenon, etc.) in women than men.
26 y is likely to confer benefit in SSc-related Raynaud's phenomenon, further research is required to co
27 (VAS) to evaluate SSc organ system symptoms, Raynaud's phenomenon, gastrointestinal (GI) tract and lu
28 al studies of large cohorts of patients with Raynaud's Phenomenon have addressed the predictors of de
29 95% CI, 1.1 to 2.4, respectively), developed Raynaud's phenomenon (HR, 1.9; 95% CI, 1.1 to 3.6) or dy
30 uggested that more than one defect may cause Raynaud's phenomenon, including increased alpha-2 sympat
31                                              Raynaud's phenomenon is characterised by episodic vasosp
32  approach to the management and treatment of Raynaud's phenomenon is emerging.
33 p1 were white women with fatigue, arthritis, Raynaud's phenomenon, malar rash, and photosensitivity.
34 thin 24 months of the onset of the first non-Raynaud's phenomenon manifestation of SSc.
35 fication criteria in less than one year from Raynaud's Phenomenon onset (Early Onset Subset-EOS), and
36                 ACA was also associated with Raynaud's phenomenon (p = 6.8 x 10(-11)) in RA.
37 d artery stiffness as well as prevalences of Raynaud's phenomenon, pulmonary hypertension, and athero
38                                              Raynaud's phenomenon (RP) affects 3-9% of the general po
39 d dosage, in 210 patients with lcSSc or with Raynaud's phenomenon (RP) and the presence of SSc-specif
40                                     Although Raynaud's phenomenon (RP) in adults is frequently report
41                                              Raynaud's phenomenon (RP) is a common disorder, yet its
42                                              Raynaud's phenomenon (RP) is a common vasospastic disord
43                                              Raynaud's phenomenon (RP) is a peripheral circulatory di
44 e or absence of 1) lupus skin disease and 2) Raynaud's phenomenon (RP) was determined for each patien
45 imination between patients with SSc, primary Raynaud's phenomenon (RP), and healthy controls.
46 uring recovery from cooling in patients with Raynaud's phenomenon secondary to scleroderma.
47 ing an acute cold challenge in patients with Raynaud's phenomenon secondary to scleroderma.
48 lassified by including the time of the first Raynaud's phenomenon symptom in the definition.
49 ogressive SSc and a more recent onset of non-Raynaud's phenomenon symptoms had higher numbers of mast